Previously we reported that viramidine is a prodrug of ribavirin and that adenosine deaminase catalyses viramidine deamination to ribavirin in vivo. This in vivo study explores this prodrug conversion in rats and inhibition by a potent adenosine deaminase inhibitor, 2′ ′-deoxycoformycin. We found that conversion of viramidine to ribavirin was viramidine dose-dependent in rat plasma. A single intravenous dose of 0.25 mg/kg 2′ ′-deoxycoformycin suppressed orally administered viramidine conversion to ribavirin in plasma by 50%. The inhibition was 2′ ′-deoxycoformycin dose-dependent and a single dose of 2 mg/kg decreased the ribavirin/viramidine area under the concentration-time curve between 0 h and 6 h ratio by 2.5-fold. These findings provide strong evidence that adenosine deaminase plays a major role in converting viramidine to ribavirin in vivo.
The epidemics caused by pathogenic viruses, such as human immunodeficiency virus and hepatitis C virus, and most recently the severe acute respiratory syndrome by a coronavirus, represent major global health hazards and demand novel broad-spectrum antiviral intervention. Although discovered more than 30 years ago, ribavirin remains the only approved small molecule drug that is active against both DNA and RNA viruses (Sidwell et al., 1972) by acting as a pleiotropic agent (Tam et al., 2001) . The active form of ribavirin in vivo includes its three 5′-phosphorylated derivatives. Together they exert antiviral activity by interfering with several critical steps required for viral replication, including host nucleotide biosynthesis, viral genome transcription and translation. The known enzymatic targets of ribavirin and its derivatives comprise host inosine monophosphate dehydrogenase, RNA guanylyl transferase, and viral RNA polymerase. Moreover, ribavirin may act as a viral mutagen by incorporation into a viral genome to induce transitional mutation and to drive the virus to error catastrophe (Crotty et al., 2000) . In addition, ribavirin is a small molecule immunomodulator that enables T-cell mediated immunity to eliminate intracellular viral pathogens.
Despite its success as an effective antiviral, the clinical use of ribavirin suffers from severe dose-limiting hemolytic anaemia. Following absorption, ribavirin is transported into red blood cells (RBCs) in which it is phosphorylated and accumulated intracelluarly to a very high level, culminating in haemolytic anaemia. As many as 20% of treated patients develop ribavirin-induced haemolytic anaemia, resulting in dose reduction or discontinuation of therapy (Fried, 2002) . As a 3-carboxamidine derivative of ribavirin, viramidine, is currently under intensive investigation in an attempt to deliver more ribavirin to the liver and reduce ribavirin trapping in RBCs, thereby improving therapeutic index (Wu et al., 2003a) (Figure 1) The antiviral activity profile of viramidine is similar to that of ribavirin in many in vitro and animal studies (Witkowski et al., 1973; Gabrielsen et al., 1992) . It is active against both RNA and DNA viruses, including vaccinia virus, respiratory syncytial virus, influenza viruses, sandfly fever virus, Punta Toro virus, herpes simplex virus, rhinovirus and parainfluenza virus. Its immunomodulatory properties are comparable to those of ribavirin both in vitro and in vivo (Barnard, 2002) . Current evidence suggests that viramidine by itself does not possess any direct antiviral activity. Its biological activity observed in cell culture and in vivo animal models is likely derived from ribavirin generated by a prodrug mechanism (Wu et al., 2003a; Wu et al., 2003b) . In addition, viramidine may serve as a catabolic inhibitor for ribavirin and prevent ribavirin from phosphorolysis by inhibiting purine nucleoside phosphorylase ( Figure 1) (Wu et al., 2004) . More importantly, viramidine exhibits a more desirable drug tissue distribution profile than ribavirin. Unlike ribavirin, animal studies indicate that viramidine is not efficiently taken up by RBCs. Instead it has a better liver enriching property that enables it to accumulate in the liver three times as much as ribavirin (Lin et al., 2003b) . Owed to this favourable liver-enrichment property coupled with a reduced propensity to accumulate in RBCs, viramidine has the potential to be a safer alternative to ribavirin, which could provide improved clinical benefits to hepatitis C virus (HCV) patients. Viramidine is currently in clinical trials with pegylated interferon-α for the treatment of chronic HCV infection.
Pharmacokinetic and metabolic analyses indicate that viramidine can be adequately converted to ribavirin in vivo (Lin et al., 2003b) . To understand this in vivo metabolic conversion and comprehend the mechanism of viramidine's action, we previously investigated the enzymatic mechanism of viramidine conversion to ribavirin. Using a purified mammalian adenosine deaminase (ADA), we discovered that ADA catalyses viramidine deamination and converts it to ribavirin in vitro (Wu et al., 2003b) . However, kinetic analyses indicate that this prodrug activation process is inefficient due to a very high Michaelis constant (K m ) for viramidine (Wu et al., 2003b) . These results shed some doubt of whether ADA is the physiological enzyme that converts most viramidine to ribavirin in vivo.
ADA is a ubiquitous enzyme in purine nucleotide metabolism and is responsible for hydrolytic deamination of adenosine or deoxyadenosine to inosine or deoxyinosine (Van der Weyden and Kelley, 1976) . Its function is crucial for immune competence. Kinetically, ADA catalyses adeno-sine deamination with a catalytic efficiency close to the diffusion rate. Because of this enormous catalytic power, ADA is capable of recognizing many unorthodox substrates for deamination. Notably, pharmacological activity and pharmacokinetic properties of several drugs have been improved by development of ADA-catalysed prodrugs (Wu et al., 2003a) . To assess whether ADA catalyses viramidine deamination to ribavirin in vivo, we sought to investigate viramidine conversion to ribavirin in rats and inhibition of the process by 2′-deoxycoformycin (2′-dCF).
Materials and methods
Materials 2′-dCF (Nipent™) was purchased from SuperGen, Inc. (San Ramon, CA, USA). It was prepared at 1 mg/ml in 1×Dulbecco's phosphate buffered saline, pH 7.4. Adult male Sprague-Dawley rats (200-250 g) were purchased from Charles River Labs (Wilmington, MA, USA). Viramidine and ribavirin were synthesized and purified at Valeant Pharmaceuticals (Costa Mesa, CA, USA) with a purity >98%.
In vivo drug administration and sample collection
In the in vivo experiments, 2′-dCF was always administrated intravenously (i.v.) to rats before they were orally dosed with viramidine. For the experiments to assess the effect of 2′-dCF on viramidine conversion to ribavirn, 2′-dCF was initially dosed at 0.25 mg/kg. Following an overnight fast, ten groups each with three rats received an i.v. dose of 2′-dCF at 0 (control) or 0.25 mg/kg. One hour after the 2′-dCF treatment, viramidine was administrated orally at 0.3, 1, 3, 10 or 30 mg/kg, respectively. Blood samples were withdrawn from the rats at 0.25, 0.5, 1, 2, 4, 6 and 24 h after viramidine dosing, and collected directly into heparinized vacutainer tubes. They were immediately centrifuged to harvest plasma for determination of viramidine and ribavirin concentrations. To investigate the effect of varied 2′-dCF doses on viramidine conversion to ribavirin, viramidine was orally dosed at 10 mg/kg with 2′-dCF administered i.v. at 0 (control), 0.25, 1 and 2 mg/kg, respectively. In these experiments, viramidine was dosed 30 min after the pretreatment of rats with 2′-dCF. There were three rats in each 2′-dCF dose group, and the blood samples were collected up to 24 h post viramidine dosing.
Liquid chromatography mass spectrometry (LC-MS/MS) analytic method
A LC-MS/MS method has been previously described for determining viramidine and ribavirin concentration in plasma . This method involves addition of radiolabelled viramidine and ribavirin as internal standards. All metabolites were separated by high performance liquid chromatography, identified and quantified by the LC-MS/MS system using positive electrospray ionization in the multiple reaction monitor mode. The calibration curves for viramidine and ribavirin were linear over a concentration range of 1-1,000 ng/ml. For both viramidine and ribavirin, the lower limit of quantification was 1 ng/ml.
The LC-MS/MS system consisted of an Agilent liquid chromatographic system (Agilent, Palo Alto, CA, USA) and an API 4000 mass spectrometer (Applied Biosystems, Foster City, CA USA). The liquid chromatography separation was accomplished using a Waters Atlantic column, 4.6×150 mm, 5 µm (Waters Associates, Watersbury, MA, USA), maintained at room temperature. Mobile phase A consisted of 0.1% formic acid in water. Mobile phase B consisted of 0.1% formic acid in methanol. The gradient conditions were 100% A between 0 and 1 min, 95% A and 5% B between 1 and 3.5 min, returned to 50% A and 50% B between 3.5 and 5 min, maintained at 50% A and 50% B between 5 and 6.5 min, ramped to 100% B between 6.5 and 6.6 min and returned to 100% A between 6.6 and 8 min. The mobile phases were delivered at 0.9 ml/min.
The precursor to product ion transitions were monitored at m/z 245 to 113 for ribavirin, 250 to 113 for [ 13 C]ribavirin, 244 to 112 for viramidine, and 249 to 112 for [ 13 C]viramidine. Each transition was alternately monitored with a dwell time of 150 msec. Collision activated dissociation gas was set at 6 psi, curtain gas was set at 15 (arbitrary unit). The TurboIon Spray source temperature was maintained at 650°C and the IonSpray voltage was set at 5,000 V. The nebulizer and TurboIon Spray were set at 50 and 60 psi, respectively. Unit resolution was applied for both Q1 and Q3.
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Pharmacokinetic analysis
Pharmacokinetic parameters were determined by monitoring the time-dependent concentrations and ratios of viramidine and its metabolites following a single dose, and were calculated using a non-compartmental method (Win Nonlin-2; Pharsight Corp. Mountain View, CA, USA).
The area under the concentration-time curve (AUC) was computed using a linear trapezoidal rule. The maximum concentration (C max ) in plasma and the time to reach C max (T max ), were the observed values. All the reported results are the average from three rats. Please note that for the low-dose viramidine groups at 0.3 and 1 mg/kg, the drug concentrations were not detectable in the whole 24h period. For example, at the 0.3 mg/kg dose, the ribavirin concentration was not detectable at all whereas viramidine was detectable for up to 1 h in the plasma. At the 1 mg/kg dose, the ribavirin concentration was measurable up to 1 h, whereas viramidine was detected for the first 6 h. As a result, the AUC values for the low-dose groups may carry higher errors than the higher-dose groups.
Results

Pharmacokinetics of viramidine conversion to ribavirin in rat plasma
The pharmacokinetic parameters C max, T max and AUC 0-6 h for the viramidine control groups in the absence of 2′-dCF are consistent with what have been reported ; Table 1 ). At the lowest viramidine oral dose of 0.3 mg/kg, ribavirin was not detected (<1 ng/ml) at any time points. However, at the next dose level of 1 mg/kg, ribavirin plasma C max was 8.2 ng/ml, which is well above the 1 ng/ml detection limit of the LC-MS/MS method.
As viramidine (C max =2.9 ng/ml) was detectable in plasma at the 0.3 mg/kg dose, this result suggests a few possibilities. It is possible that the ribavirin's concentration was simply too close to the analytic limit to be detected, or maybe there is a viramidine concentration barrier for transporting to plasma and converting to ribavirin. Following oral administration, viramidine was rapidly absorbed with T max between 0.25 and 0.67 h. When the dose was raised from 0.3 to 30 mg/kg, the plasma C max and AUC 0-6 h of viramidine increased proportionally from 2.9 to 180 ng/ml and 2.0 to 360 ng . h/ml respectively. Apart from the 0.3 mg/kg dose level, viramidine quickly converted to ribavirin with T max between 0.25 and 1.0 h ( Table 1 ). The higher the viramidine dose level was, the longer it took to reach T max , suggesting a limited capacity to transport viramidine to plasma.
For the plasma C max and AUC of the converted ribavirin, similar incremental relationships to viramidine dose were observed. When the viramidine dose increased from 1 to 30 mg/kg, ribavirin's C max and AUC 0-6 h in rat plasma increased linearly from 8.2 to 330 ng/ml and 5.8 to 1,400 ng . h/ml, respectively. These results indicate that the observed plasma viramidine and ribavirin concentrations roughly reflect the administrated drug dose in the system.
When viramidine dose increased from 0.3 to 1, 3, 10 and 30 mg/kg, the ratio of ribavirin and viramidine (R/V) AUC ranged from 0 to 3.9 (Table 1) . From the plot of R/V AUC ratio versus viramidine dose (Figure 2) , viramidine conversion to ribavirin increased linearly with dose in the lower dose range, but it started to reach saturation at 10 mg/kg. As the major metabolic pathways of viramidine are the conversion to ribavirin and the concurrent degradation of viramidine and ribavirin to the respective triazole nucleobase by purine nucleoside phosphorylase (Figure 1) , the observed kinetic phenomena suggests that at the lower dose, the prodrug conversion is the rate limiting step. However at the higher dose range, the formation of ribavirin and catabolism of viramidine and ribavirin started to reach equilibrium.
Effect of 2′ ′-dCF on viramidine conversion to ribavirin in rat plasma
As a potent ADA inhibitor, 2′-dCF was used to probe its inhibitory effect on viramidine conversion to ribavirin in rat blood. A single dose of 0.25 mg/kg 2′-dCF was administered i.v. to rats prior to the oral dosing of viramidine at 0.3, 1, 3, 10 and 30 mg/kg, respectively. As summarized in Table 1 , this inhibitor had a significant effect on both JZ Wu et al. 36 ©2006 International Medical Press viramidine's and ribavirin's plasma C max and AUC values. Viramidine's plasma C max was plotted against viramidine dose (data not shown), and it demonstrated that the presence of 2′-dCF approximately enhanced viramidine's C max by 51% and concurrently decreased ribavirin's C max by 23%. Specifically, at 30 mg/kg dose level, 2′-dCF increased viramidine's C max from 180 to 270 ng/ml and concomitantly reduced ribavirin's C max from 330 to 250 ng/ml. The AUC versus viramidine dose relationship highlighted the inhibitory effect of 2′-dCF on the prodrug conversion in a period of 6 h. A single i.v. administration of 2′-dCF on average raised plasma viramidine AUC 0-6h by 82% and concurrently reduced ribavirin's AUC 0-6 h by 14%. These results confirm our hypothesis that ADA is involved in converting viramidine to ribavirin in vivo. It might be expect that the increase amount of viramidine following ADA inhibition by 2′-dCF would be equal to the decrease in the amount of ribavirin, but AUC measurements did not show this. For example, at 10 mg/kg dose level, 2′-dCF enhanced viramidine's AUC 0-6 h by 100 ng . h/ml (from 130 to 230 ng . h/ml) and decreased ribavirin's AUC 0-6 h by 70 ng . h/ml (from 500 to 430 ng . h/ml). At the higher viramidine dose levels of 10 and 30 mg/kg, there seems to have been a trend in that the increase of viramidine AUC is larger than the decrease of ribavirin AUC. This disparity may be interpreted by our previous observation that viramidine is able to inhibit ribavirin catabolism and stabilize the newly synthesized ribavirin. As reported, viramidine is a potent inhibitor for purine nucleoside phosphorylase, the enzyme that degrades ribavirin (Wu et al., 2004; Willis et al., 1980) . As illustrated in Figure 1 , a higher concentration of viramidine in rat plasma as a result of ADA inhibition by 2′-dCF may prevent more ribavirin from catabolism, resulting in a higher concentration of ribavirin. If viramidine can indeed help stabilize the newly converted ribavirin, it should be responsible for the 30 ng . h/ml AUC difference of viramidine and ribavirin at 10 mg/kg dose level. To further assess the overall effect of 2′-dCF on viramidine conversion to ribavirin, we plotted R/V AUC 0-6 h ratio against viramidine dose in the presence and absence of 2′-dCF ( Figure 2) . In all viramidine dose levels, the presence of 2′-dCF suppressed the R/V AUC 0-6h ratio. Judged from the level of R/V AUC ratio in the presence and absence of 2′-dCF, the inhibition of ADA suppressed about 50% conversion. For example, at 30 mg/kg dose level, 2′-dCF increased viramidine's AUC from 360 to 640 ng . h/ml and decreased ribavirin's AUC from 1,400 to 1,200 ng . h/ml (Table 1) . The presence of 2′-dCF reduced the R/V AUC 0-6 h ratio from 3.9 to 1.9. Clearly, the ADA activity that was suppressed by the single dose of 2′-dCF accounts for about 50% of viramidine conversion as detected in plasma. As a single dose of 0.25 mg/kg 2′-dCF may not completely inhibit ADA activity in vivo in all the compartments of animal body for a period of 6 h, it is possible that ADA accounts for more than 50% of viramidine conversion.
Dose-dependent inhibition of viramidine conversion to ribavirin by 2′−dCF
We further investigated 2′-dCF's dose effect on viramidine conversion to ribavirin. In these experiments, viramidine was orally dosed at 10 mg/kg with 2′-dCF i.v. administered at 0 (control), 0.25, 1 and 2 mg/kg respectively. Compared to the previous experiments, viramidine was dosed 30 min after pretreatment of rats with 2′-dCF. For clarity, only AUC 0-6h and AUC last (0 to 24 h) are listed in Table 2 . Clearly, viramidine's AUC augments at the higher doses of 2′-dCF, whereas ribavirin's AUC stays about same regardless of 2′-dCF's dose. The inhibitory effect of 2′-dCF on viramidine conversion to ribavirin manifests by plotting the R/V AUC 0-6 h ratio versus 2′-dCF dosage (Figure 3) . The higher the 2′-dCF dose is, the lower the R/V AUC 0-6 h ratio. Interestingly, the curve is exponentially decayed instead of being linear, suggesting that the inhibition is tight-binding. This kinetic is constant with the report that 2′-dCF is an extremely tightbinding inhibitor for ADA (Agarwal et al., 1977) . Comparing the R/V AUC 0-6 h ratio at the highest 2′-dCF dose tested (2 mg/kg) to the control group, it is markedly Table 2 . Effect of various doses of 2′-dCF on the AUC of viramidine and ribavirin in rat plasma* reduced by 2.5-fold (Table 2) . Taken together, 2′-dCF is a potent inhibitor that is capable of suppressing viramidine conversion to ribavirin in vivo. The relatively constant ribavirin AUC at varied 2′-dCF dosage implies that 2′-dCF could possess some stability effect on ribavirin to prevent it from catabolism, although more experiments are needed to address this possibility. Finally, both viramidine's and ribavirin's AUC last increased significantly compared with their AUC 0-6 h values (Table 2) . However, the R/V AUC last is higher than that of AUC 0-6h , suggesting that the inhibition of this prodrug conversion becomes loose in the later hours in the experiments.
Discussion
2′-dCF is an approved chemotherapy drug for the treatment of hairy cell leukaemia. It is extremely potent against ADA with an inhibition constant (K i ) as low as 2.5 pM (Agarwal et al., 1977) . 2′-dCF has an advantage of being an effective probe for adenosine metabolism due to its extremely high affinity and specificity for ADA (Padua et al., 1990) , and the fact that it is not metabolized in rat plasma (Borondy et al., 1977) . According to the literature, any physiological effects in small animals at a low dose of 2′-dCF such as 0.25 mg/kg should be due to the specific inhibition of ADA. The pharmacokinetics of inhibition of ADA by 2′-dCF has been investigated in detail in rats and dogs (Chassin et al., 1979) . 2′-dCF is quickly absorbed and widely distributed throughout the most parts of the animal body. A daily intraperitoneal (i.p.) dose of 0.25 mg/kg 2′-dCF has been reported sufficient to suppress the majority of ADA activity in many tissues of rat or dog. The route of administration, i.v. or i.p., is believed to have little effect on the tissue distribution of 2′-dCF. Although the half-life of 2′-dCF in plasma is only 15 min, when the drug is dosed i.v. at 0.25 mg/kg, its plasma concentration is maintained at more than 50 nM at the end of 6 h period, which is more than 1,000-fold higher than the K i for ADA (Chassin et al., 1979) . Based on these data, we decided to initially assess the effect of 2′-dCF on viramidine conversion with a single i.v. dose of 2′-dCF at 0.25 mg/kg. To be consistent with clinical regimen, viramidine was administered orally to rats. We determined the level of viramidine conversion to ribavirin mainly by their respective AUC 0-6 h in their plasma. Since there was some variation of the AUC values among the studied animals in the same group, we found that the R/V AUC ratio determined for each animal is a better and consistent indicator for the degree of viramidine conversion to ribavirin. Using this R/V AUC ratio as the criteria, we found that a single dose of 2′-dCF at 0.25 mg/kg suppressed orally administered viramidine conversion to ribavirin in the rat plasma by 50%. Moreover, this inhibition was 2′-dCF dose dependent, and a single dose of 2 mg/kg 2′-dCF decreased the R/V AUC 0-6 h ratio by 2.5-fold. These findings provide strong evidence that adenosine deaminase plays a critical role in converting viramidine to ribavirin in vivo as suggested from our previous in vitro studies (Wu et al., 2003b) . Although 2′-dCF significantly inhibits viramidine conversion to ribavirin in vivo, a considerable amount of ribavirin remains in the rat plasma regardless of 2′-dCF dose. The lack of complete inhibition implies a few possibilities. Firstly, viramidine and 2′-dCF were administered through different routes. Viramidine was delivered through the oral route. Based on the whole body autoradiography of rats after treatment with [ 14 C]viramidine, the drug is enriched in the liver and small and large intestines where the prodrug conversion mainly occurs (Wu et al., 2003a; Lin et al., 2003b) . The ribavirin detected in the plasma should reflect the drug converted in plasma as well as in other compartments, as the converted ribavirin in the liver and intestine can be absorbed into plasma as illustrated in Figure 1 . On the other hand, 2′-dCF was i.v. dosed. 2′-dCF is known to have a very short half-life in plasma. For a 0.25 mg/kg i.v. dose, the drug plasma concentration could drastically decrease in a period of 6 h. Although 2′-dCF should completely suppress ADA activity in plasma as predicted by plasma concentration, it may not sustain enough concentration to inhibit ADA activity in other compartments, especially in Figure 3 . The effects of varied dose of i.v. 2′-dCF on the ratio of ribavirin and viramidine AUC 0-6 h when viramidine was dosed orally at 10 mg/kg the liver and intestines where the prodrug conversion happens (Figure 1) . Secondly, a potent inhibitor like 2′-dCF is also known to have slow 'on' and 'off' kinetics. Although we have pretreated rats with 2′-dCF before dosing viramidine, there is still a slim possibility that it cannot completely suppress ADA activity due to its unique slow inhibition kinetics.
Thirdly, ADA can be regenerated in some rat tissues (Chassin et al., 1979) . The newly synthesized ADA may not be completely inhibited by the diminishing 2′-dCF in the 6 h period. These new enzymes could help turn over some viramidine substrates.
Lastly, there is a possibility that other enzyme(s) in addition to ADA and/or a spontaneous deamination process concomitantly contribute to viramidine conversion to ribavirin.
Rat and human ADA enzymes share overall 86% of amino acid sequence identity. They have essentially the same active site and have similar substrate specificity and sensitivity to various inhibitors (Wilson et al., 1991) . Therefore, the results obtained here are highly relevant to human system. From this study, we can conclude that ADA-catalysed deamination is the major route to convert viramidine to ribavirin in vivo.
